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Abstract
Apolipoprotein E (APOE) genotype is believed to play a role in the onset of dementia, though
less is known about its relationship with non-pathogenic age-related cognitive decline. We
assessed whether APOE was a risk factor for cognitive decline among older Taiwanese
adults using nationally representative data. General cognition was measured longitudinally
over eleven years; domain-specific cognitive assessments of working memory, declarative
learning and three aspects of attention (executive function, alerting, and orientation) were
performed once. Having at least one risky APOE allele was associated with more rapid lon-
gitudinal cognitive decline compared to those with no risky alleles. Some evidence from the
cross-sectional analysis of domain-specific cognitive assessments suggested that APOE
genotype may be more closely associated with working memory and declarative learning
than with attention. Most genetic studies of cognition include only populations of European
descent; extension is crucial. This study confirmed the association between APOE geno-
type and the rate of cognitive decline in a predominantly Han Chinese population. Additional
studies on diverse populations are warranted.
Introduction
Dementia and cognitive decline are major public health concerns that will only become bigger
and more costly with the aging of the world’s population. The estimated current prevalence of
dementia among those aged 60 and above is approximately 5–7% in regions around the world,
and the number of people suffering from dementia is expected to double every twenty years if
current trends continue [1]. Even without a diagnosable disease, cognitive decline is a hallmark
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of aging. In fact, a substantial portion of late life cognitive decline cannot be accounted for by
common neurodegenerative pathologies, such as Alzheimer’s disease and cerebrovascular dis-
ease [2]. Age-related cognitive decline has a major impact on quality of life, and carries high
societal and personal costs [3]. There is extensive heterogeneity in cognitive decline among
older adults [4], and the determinants of these varying trajectories are not well understood.
Genetic factors are believed to be major risk factors for the development of Alzheimer’s dis-
ease. Best known is the ε4 allele of the apolipoprotein E gene (APOE), a well-established
genetic risk factor for late-onset (after age 65) Alzheimer’s disease [5,6]. The ε4 allele is esti-
mated to explain 4–6% of the variance in Alzheimer’s disease [7], and is expressed in more
than half of Alzheimer’s disease patients [8]. APOE regulates cholesterol metabolism and is
believed to modulate the clearance of amyloid-beta, the accumulation of which is a hallmark of
Alzheimer’s disease [9,10]. The precise biological mechanism linking APOE genotype and Alz-
heimer’s disease, however, is not well-understood [8,11].
There is some evidence that APOE is associated with age-related cognitive decline that is
not attributable to Alzheimer’s disease. Several studies have found an association between ε4
status and cognitive ability among those not suffering from dementia. Among non-demented
Dutch [12] and white American [13] study participants, APOE genotype predicted memory
scores. Wisdom et al.’s 2011 meta-analysis of non-demented individuals [14] found that
APOE ε4 carriers performed worse than non-carriers on measures of episodic memory, execu-
tive functioning, and overall cognitive ability. Several studies have found evidence that APOE
genotype is associated with change in cognitive ability as well. Studies of predominantly white
Americans (which excluded those with Alzheimer’s disease or mild cognitive impairment)
found more rapid longitudinal declines in memory among ε4 carriers compared to non-carri-
ers [13,15]. A genome-wide association study (GWAS) of non-demented British and Swedish
participants implicated APOE in longitudinal declines across a number of cognitive tests of
fluid-type intelligence [3]. However, several authors [11,16,17] argue that any association
between APOE and cognitive decline is largely or entirely attributable to pre-clinical Alzhei-
mer’s disease, and thus APOE may not play a role in non-pathogenic decline.
Most genetic studies of cognition have been conducted on individuals of European ances-
try, despite evidence that risk genes may act differently in different populations. For example,
one US-based study found that APOE was associated with Alzheimer’s disease only among
white, but not black or Hispanic, respondents [18]; another US study found a similar effect of
APOE for predicting Alzheimer’s disease in white and black respondents, but substantial race
differences in the effect size of other risk genes [19]. If the association between APOE genotype
and Alzheimer’s disease risk varies by race/ethnicity, then this may be the case for age-related
cognitive decline as well, though no study of which we are aware has directly addressed this
question.
There is a critical need to examine the relationship between APOE genotype and cognition
in non-Western populations. Replication of an association in multiple populations of different
ethnicities strengthens the case that a particular genetic variant is responsible for the trait of
interest. Questions remain about whether genetic risk factors found in European populations
also hold in Asian populations, and research has thus far been limited. Several studies of Alz-
heimer’s disease in Han Chinese populations have confirmed a link between Alzheimer’s dis-
ease and APOE genotype [20,21], however the prevalence of the APOE ε4 allele among those
diagnosed with Alzheimer’s disease has been found to vary substantially across geographic
regions [22], suggesting that APOE genotype may be a more important determinant of Alzhei-
mer’s disease risk among certain populations.
As for white European-ancestry populations, results on APOE and non-pathogenic cogni-
tive decline in Asian populations have been mixed. In a Korean population, APOE genotype
APOE and cognitive decline
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was not associated with age-related cognitive decline [23] (though it was associated with Alz-
heimer’s disease risk [24]). By contrast, studies of Chinese elders found that APOE was associ-
ated with age-related cognitive decline [25], as well as cross-sectional cognitive ability [26].
In this study, we examined whether APOE genotype was associated with age-related cogni-
tive decline among cognitively healthy older Taiwanese adults. A major strength of this study
is the richness of the cognitive assessments. A summary ten-item cognitive measure meant to
reflect general cognition was assessed longitudinally, up to five times per respondent over the
course of eleven years. In addition, in the final wave of data collection, respondents completed
a number of detailed cognitive tasks designed to measure three aspects of attention (executive
functioning, orienting, and alerting), working memory, and declarative learning, allowing for
cross-sectional analysis of these individual cognitive domains.
Materials and methods
The analyses described below were reviewed by the Institutional Review Board of Columbia
University Medical Center and determined to be exempt (protocol # AAAQ4212).
Data
The Taiwan Longitudinal Study of Aging (TLSA) is an ongoing nationally representative study
of Taiwanese adults aged 50 or older. Begun in 1989, TLSA has conducted follow-up surveys
every 3–4 years, with refresher samples of younger individuals added in each wave. TLSA
asked respondents detailed questions about their health, including a ten-question general cog-
nitive assessment.
A random subset of the TLSA sample was recruited for the Social Environment and Bio-
markers of Aging Study (SEBAS), which was conducted in 2000, 2006, and 2011. SEBAS par-
ticipants were asked to complete a hospital examination that allowed for collection of an
extensive set of biomarkers, including deoxyribonucleic acid (DNA; from blood), in 2000 and
2006. Some of the selected TLSA participants (n = 111 in 2000 and n = 32 in 2006) were
deemed ineligible for the SEBAS examination due to poor health. See Chang [27] for addi-
tional details of SEBAS sample construction. The cognitive assessment from TLSA was repli-
cated in SEBAS waves; thus, comparable assessments were made in 2000, 2003, 2006, 2007,
and 2011.
There were 1,420 unique respondents who completed the SEBAS examination in 2000
(n = 1,023) and/or 2006 (n = 1,036) and were asked to give DNA samples. Of these, 8 respon-
dents did not have valid APOE data because the respondent didn’t consent to store DNA
(n = 7), or the respondent refused blood collection (n = 1).
For the longitudinal analysis of the summary cognitive measure, we did not include respon-
dents with missing demographic information on sex (n = 0), age (n = 0), or education (n = 23)
or who didn’t complete at least one general cognitive assessment between 2000 and 2011
(n = 10). This resulted in an analytic sample size of 1,379. Most respondents (68%) participated
in all available cognitive assessments, meaning 2000, 2003, 2006, 2007, and 2011 for respon-
dents who joined SEBAS in 2000, and 2006, 2007, and 2011 for those who joined SEBAS in
2006.
Of those respondents in the longitudinal analysis, 985 participated in the 2011 SEBAS sur-
vey. However, not all had a valid performance measure for at least one of the detailed cognitive
tasks measured in 2011. Some participants (n = 65) were interviewed by proxy (and thus did
not complete the cognitive portion of the survey) due to serious illness (n = 32), deafness/
being hard of hearing (n = 17), mental illness/senility (n = 11), inability to comprehend the
survey (n = 2), being unwilling to complete the survey (n = 1) or other reasons (n = 2). An
APOE and cognitive decline
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additional 111 respondents declined to participate in the cognitive assessment or failed to
complete any valid trials for any of the tasks. Thus, there were 809 respondents with informa-
tion from at least one of the detailed cognitive tasks. Because not every respondent had valid
performance measures for all of the tasks, the sample size varied between 724 and 793 for these
analyses.
Due to the nature of the sample construction, those included in our analyses were likely
healthier than the general SEBAS population. We explore health and mortality selection in S1
Appendix.
Measures
Summary cognitive measure. Overall cognition was assessed in 2000, 2003, 2006, 2007
and 2011 with ten cognitive and memory tasks, listed in Table 1. The tasks were derived from
the Short Portable Mental Status Questionnaire [28], the Rey Auditory Verbal Learning Test
[29,30], and a modified Digits Backward test from the Wechsler Adult Intelligence Scale [31].
Many of the tasks correspond to items used in the Chinese versions of the Mini-Mental Status
Examination [32,33]. See Chang et al. [27] for further details of the cognitive tasks. Following
the practices of Herzog and Wallace [34], the ten tasks are summed to create an overall score
ranging from 0 to 24. If a respondent did not answer a task, it was coded as incorrect. These
tasks have been analyzed in this fashion in prior studies of this population [35,36]; however,
this cognitive measure is not directly comparable to a validated cognitive scale used in other
populations.
Detailed cognitive measures. Detailed cognitive measures were collected from SEBAS
respondents only in the 2011 wave, with a series of tasks designed to measure attention, work-
ing memory, and declarative learning. All detailed cognitive tasks were designed by the Brain
and Language Lab at Georgetown University.
Three aspects of attention (executive function, alerting, and orientation) were assessed with
an Attention Network Task (ANT) based on prior work by Fan et al. [37] and Costa et al. [38].
In this task, participants were shown a row of five arrows, and asked to indicate the direction
of the central arrow. The four flanking arrows could be pointing the same way (congruent) as
the middle arrow, or the opposite way (incongruent), and could be preceded by various cues
Table 1. Questions included in the longitudinal summary cognitive assessment.
Item Max score Source
Tell me your address 1 SPMSQ
What is today’s date? (Year, month and day) 3 SPMSQ
What day of the week is it? 1 SPMSQ
How old are you this year? 1 SPMSQ
What is your mother’s maiden name? 1 SPMSQ
Who is the current president? 1 SPMSQ
Who was the president before him? 1 SPMSQ
Serial 3s subtraction task (4 times, starting at 20) 4 SPMSQ
10-item recall task (dog, cloth, watermelon, etc.) 10 RAVL
5 numbers repeated in reverse order task 1 WAIS
Total 24
SPMSQ = Short Portable Mental Status Questionnaire
RAVL = Rey Auditory Verbal Learning Test
WAIS = Wechsler Adult Intelligence Scale
https://doi.org/10.1371/journal.pone.0206118.t001
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indicating where the central arrow might appear. The task was repeated many times with vari-
ation in the congruency and cue. Executive function was measured as the conflict effect, the
difference in response time between congruent and incongruent trials. The alerting effect was
measured as the difference in performance between trials with a cue and no cue. The orienting
effect was measured as the difference in performance between trials with a cue placed exactly
where the middle arrow would appear and trials with a cue placed in the center of the screen.
Working memory was evaluated via an adapted N-back task [39]. In the N-back task,
respondents were shown a series of single digits, then asked whether the current digit was the
same as the digit shown N items ago. For example, a respondent might be shown the following
sequence of numbers: 2-5-3; the correct answer for the 1-back task would be 5, while the cor-
rect answer for the 2-back test would be 2. SEBAS participants completed 1-back and 2-back
tasks. Further details of the N-back task are available in [40].
Declarative learning was assessed by a task designed by the Brain and Language Lab [41],
wherein respondents were shown images of real and novel (imaginary) objects. After a delay
of several minutes, the respondents were shown another set of images, some new and some
repeated, and asked whether they had previously seen the object. Scores for declarative learn-
ing were assessed from the recognition phase of the task, that is, the period after the delay.
Performance was assessed by calculating response time for executive function, alerting, and
orienting, and D’ scores for the N-back and declarative learning tasks. D’ is a measure of accu-
racy that quantifies discrimination between signal and noise. A D’ of zero indicates chance
performance, higher positive values indicate better discrimination, and negative values indi-
cate reverse discrimination (effective range -4.6 to 4.6). For details see Stanislaw and Todorov
[42].
Genotyping. APOE genotype was determined by Union Clinical Laboratories in Taipei,
Taiwan as described in Vasunilashorn et al. [43]. Briefly, DNA was extracted from whole
blood, then amplified with polymerase chain reaction amplification refractory mutation sys-
tem and polymerase chain reaction restriction fragment length polymorphism analysis.
Analytic strategy
Longitudinal analysis. To model individuals’ change in cognitive ability over time, we
used age-based growth curves. This allowed us to determine whether those with at least one ε4
allele followed steeper trajectories of decline per year of age compared to those with no ε4
alleles. All models controlled for sex (by including an indicator variable for female), years of
education (centered at six years, close to the mean), and, implicitly, age.
For respondents genotyped in 2000, we used all cognitive test measures taken in 2000 or
later, for up to five cognitive measures (2000, 2003, 2006, 2007, 2011). For those not genotyped
until 2006, we used only cognitive test results available in 2006 or later.
Cross-sectional analysis. For the cross-sectional analysis of specific cognitive domains,
we used linear regression models to examine the association between APOE genotype and the
detailed cognitive assessments taken in 2011. As with the longitudinal analysis, all models con-
trolled for sex, education, and age.
Results
Longitudinal analysis of summary cognitive measures
Descriptive statistics of the analytic sample are shown in Table 2. The sample, comprised of
the original SEBAS study cohort as well as younger refresher samples added in later years, had
an average age of 68 years in 2000, 67 years in 2006, and 70 in 2011. The respondents had rela-
tively low educational attainment: just 6 years on average. Most respondents (72%) were
APOE and cognitive decline
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genotyped based on a blood sample taken in 2000; the remaining respondents were genotyped
from a 2006 blood sample. Respondents had up to five valid cognitive scores, measured in
2000, 2003, 2006, 2007, and 2011. Respondents had 3.6 cognitive scores on average; 80% of
respondents had three or more. Further details of the cognitive scores and measures are shown
in S1 Fig.
Table 3 shows results from the age-based growth curve models of cognitive scores between
2000 and 2011. In these models, the intercept (cognitive score at age 65) and slope (change in
cognitive score per year of age) were allowed to vary randomly above and beyond the system-
atic differences associated with covariates in the model. Model 1 shows the association between
having at least one APOE ε4 allele and cognitive score, and Model 2 adds an ε4 status � age
interaction. The risk associated with the ε4 allele was modeled as dominant, meaning one or
more copies of the risky allele was assumed to convey risk. In this sample, very few respon-
dents (0.4%) were homozygous for the ε4 allele, so the results from an additive risk model—
wherein each additional ε4 allele conveys additional risk—were nearly identical to the domi-
nant risk model (additive risk model results not shown). All models included sex and educa-
tion as covariates.
Table 2. Descriptive statistics of the longitudinal general cognition sample.
Mean or % SD Median N
Female 44.4% — — 1,379
Age
2000 68.0 8.4 68.0 976
2003 70.4 8.1 70.0 858
2006 66.8 10.1 65.0 1,102
2007 67.3 10.0 66.0 1,100
2011 69.8 9.3 68.0 919
Age when genotyped� 64.7 8.9 62.0 1,374
Year genotyped�
2000 71.7% — —
2006 28.3% — —
Education, years 6.3 4.8 6.0 1,379
Summary cognitive score [range 0–24]
2000 16.6 3.6 17.0 976
2003 15.4 3.9 16.0 858
2006 16.4 3.7 17.0 1,102
2007 16.2 3.9 17.0 1,100
2011 15.9 4.0 17.0 919
Number of summary cognitive score
measures
3.6 1.3 3.0 1,379
One cognitive score 8.0% — —
Two cognitive scores 11.6% — —
Three cognitive scores 30.5% — —
Four cognitive scores 12.8% — —
Five cognitive scores 37.1% — —
APOE genotype 1,379
Two risk alleles 0.4% — —
One risk allele 13.9% — —
Zero risk alleles 85.8% — —
� Date of genotyping was missing for 5 respondents.
https://doi.org/10.1371/journal.pone.0206118.t002
APOE and cognitive decline
PLOS ONE | https://doi.org/10.1371/journal.pone.0206118 October 19, 2018 6 / 14
Model 1 estimated cognitive score trajectories as a function of having at least one APOE
risk allele (ε4). In this model, the mean cognitive score for a 65-year-old man with six years of
education was 16.7 points (out of 24 total). Cognitive scores declined with age: each year of age
was associated with a 0.16-point score reduction. The standard deviations of the intercept and
slope shown in Model 1 indicate that there was statistically significant (p<0.05) respondent-
level variation in the cognitive score at age 65 and in the annual rate of change in the cognitive
score. The correlation between the intercept and slope, estimated at 0.50, indicates that respon-
dents with lower baseline cognitive score were also more likely to have steeper declines in cog-
nitive score with increasing age compared to respondents with higher baseline cognitive
scores. Model 1 shows that APOE genotype was not significantly associated with cognitive
score at age 65 (95% CI (-0.393, 0.283)).
Model 2 adds an APOE genotype�age interaction to test whether ε4 status was associated
with a more rapid annual decline in cognition. The point estimates for the constant term and
the age term were very similar to those in Model 1, and again APOE genotype was not signifi-
cantly associated with cognitive score at age 65 (95% CI (-0.474, 0.209)). However, APOE
genotype was significantly associated with the annual rate of decline in cognition. Respondents
with at least one APOE ε4 allele had an additional .06-point decline in cognitive score per year
of age compared to respondents with no ε4 alleles. Thus, the age-related decline in cognitive
score was approximately 40% steeper for those carrying an ε4 allele (-0.22 points per year of
age) than for those with no ε4 alleles (-0.16 points per year of age). To put this in context, a
respondent with at least one ε4 allele experienced in five years the same decline in cognitive
score that would be expected from about seven years of aging in a respondent with no ε4
alleles, on average.
Table 3. Coefficients and 95% confidence intervals from growth curve models of longitudinal cognitive score,
2000–2011.
(1) (2)
Beta/95% CI Beta/95% CI
Constant 16.666 16.674
(16.487, 16.844) (16.495, 16.853)
Age, centered at 65 -0.163 -0.154
(-0.177, -0.149) (-0.170, -0.139)
At least one ε4 allele -0.055 -0.132
(-0.393, 0.283) (-0.474, 0.209)
At least one ε4 allele � age -0.063
(-0.103, -0.024)
SD(slope) 0.132 0.129
(0.112, 0.156) (0.109, 0.154)
SD(intercept) 1.651 1.657
(1.522, 1.792) (1.527, 1.798)
Corr(intercept, slope) 0.501 0.501
(0.328, 0.641) (0.326, 0.643)
SD(residual) 2.311 2.310
(2.254, 2.370) (2.253, 2.369)
Number of observations 4,955 4,955
Number of respondents 1,379 1,379
P-value from joint test of ε4 & ε4�age 0.006
Note: All models included sex (a female indicator variable) and years of education (centered at 6 years) as covariates.
https://doi.org/10.1371/journal.pone.0206118.t003
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Cross-sectional analysis of detailed cognitive measures
Summary statistics of the sample included in the cross-sectional analyses are shown in Table 4.
While the longitudinal analysis included respondents who were genotyped in 2000 or 2006
and contributed at least one summary cognitive measure, this cross-sectional analysis was fur-
ther limited to respondents who completed at least one of the detailed cognitive assessments in
2011 (n = 809). The minimum age was higher in the cross-sectional analysis than the longitu-
dinal analysis (58 vs. 53), though the average age of 2011 participants was about the same in
the two analyses (69.3 vs 69.8 years), indicating that mortality and health selection played a
role in participation in the detailed cognitive assessments (see S1 Appendix for more details).
The cross-sectional analyses of the detailed cognitive tasks assessed in 2011 are shown in
Tables 5 and 6. Linear regression models were used to estimate whether domain-specific cog-
nitive ability was associated with APOE genotype (Table 5), and whether APOE genotype
modified the age-cognition relationship (Table 6). Columns 1–8 show the results for models of
D’ for the N-back task (columns 1–2) and the declarative learning task (columns 3–5), and of
response time differences for the attention tasks: conflict (executive function, column 6), alert-
ing (column 7), and orienting (column 8). Each model also included a constant term, and sex
and education covariates (coefficients not shown).
The cross-sectional results provided mixed findings regarding the effect of the ε4 allele.
Having at least one ε4 allele of APOE was significantly associated with worse performance
on the 2-back task at age 65 (0.25 worse D’; Table 5, column 2), and the real objects portion of
the recognition phase from the declarative learning task (0.13 worse D’; Table 5, column 4).
APOE genotype was not significantly associated with performance on the 1-back task or the
novel objects portion of the declarative learning task (Table 5, columns 1 and 5), nor was it
Table 4. Descriptive statistics of the cross-sectional detailed cognition sample.
Mean or % SD Med. N
Female 46.8% — — 809
Year genotyped
2000 58.9% — —
2006 41.1% — —
Age, 2011 69.3 9.1 67.0 809
Age when genotyped 61.2 7.0 59.0 806
Education, years 7.2 4.7 6.0 809
Summary cognitive score [range 0–24]
2011 16.4 3.4 17.0 800
Detailed cognitive measures, 2011 4.1 1.0 5.0 809
1-back, D’ 2.1 1.3 2.4 787
2-back, D’ 1.3 1.1 1.3 787
Declarative learning, overall, D’ 0.7 0.5 0.7 793
Declarative learning, real objects only, D’ 0.9 0.8 0.9 793
Declarative learning, novel objects only, D’ 0.4 0.4 0.4 793
ANT: conflict effect, response time (ms) 48.6 75.5 47.8 724
ANT: alerting effect, response time (ms) -1.9 61.5 0.3 725
ANT: orienting effect, response time (ms) 15.3 70.9 13.8 725
APOE genotype 809
Two risk alleles 0.4% — —
One risk allele 13.5% — —
Zero risk alleles 86.2% — —
https://doi.org/10.1371/journal.pone.0206118.t004
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associated with response time for any of the three attention tasks (Table 5, columns 6–8). Age
was significantly associated with worse performance on both N-back tasks and both the real
and novel objects portions of the declarative learning task (Table 5, columns 1–5), but was not
associated with response time for any of the attention tasks (Table 5, columns 6–8). The APOE
genotype � age interaction was not statistically significant in any models (Table 6), suggesting
that ε4 status may not alter the association between age and performance on these cognitive
tasks.
Discussion
The goal of this study was to test whether APOE genotype, which has been strongly implicated
in Alzheimer’s disease, was associated with age-related cognitive decline among cognitively
healthy older Taiwanese adults. In growth curve models using a general cognitive measure
Table 5. Coefficients and 95% confidence intervals from cross-sectional linear regression models of detailed cognitive assessments, 2011: Regression models of
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Age, centered at
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(-1.162, 0.181) (-0.553, 0.541) (-0.151, 1.105)
N 787 787 793 793 793 724 725 725
https://doi.org/10.1371/journal.pone.0206118.t005
Table 6. Coefficients and 95% confidence intervals from cross-sectional linear regression models of detailed cognitive assessments, 2011:: Regression models of
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All models included age, sex, and years of education.
https://doi.org/10.1371/journal.pone.0206118.t006
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collected longitudinally, having at least one ε4 allele was associated with steeper declines in
cognitive score per year of age. However, APOE genotype was not associated with baseline
cognitive score in these models. In cross-sectional analyses of specific cognitive domains, there
was some, but not conclusive, evidence that a risky APOE genotype may be associated with
worse performance in the domains of working memory and declarative learning.
The lack of association between APOE genotype and baseline general cognitive score in our
growth curve models is surprising given several studies that have shown APOE to predict cog-
nitive performance among non-demented study participants [12–14]. However, the studies
that did show an association tended to use domain-specific measures of cognition, such as
memory [12–14] and executive functioning [14], rather than the general measure we used. It is
possible that our general cognitive measure was too noisy or broad to pick up domain-specific
effects.
Results from our cross-sectional analysis support the view that the APOE-cognition link
may be domain-specific. We found evidence suggesting that APOE may be more closely linked
to working memory and declarative learning than to attention, consistent with past work
showing that certain cognitive domains may be more affected by APOE genotype than others
[14,44]. Prior studies have found deficits in working memory among healthy carriers of the ε4
allele [45,46], suggesting that the effect of APOE on age-related cognitive decline could act via
working memory. Declarative learning has been less studied in relation to APOE, but one
early study also implicated APOE in age-related declarative learning impairment [47]. Still,
our cross-sectional results were mixed, and it is possible that the statistically significant results
we found were due to chance.
The ε4 allele of APOE has been found to be associated with longitudinal cognitive decline
in non-demented study participants [3,15,48,49]. However, nearly all genetic studies have
been conducted on populations of European descent, and there is uncertainty about whether
these associations are present in other ethnic groups; the few prior studies on Asian popula-
tions have been inconsistent [23,24]. We confirmed the relationship found in studies of Euro-
pean-ancestry individuals that a risky APOE genotype was associated with steeper age-related
cognitive decline in this population of Taiwanese older adults primarily of Chinese Han
ancestry.
This study has several limitations. First, as is always the case, a larger sample would have
been desirable; Liu et al. [50] suggested that small sample sizes could be responsible for the
mixed findings on genetics and cognition in Asian populations. Still, our sample is larger than
many of the studies Liu critiques. Second, selection bias is almost certainly at play since those
respondents who experienced the most dramatic cognitive declines were less likely to partici-
pate in cognitive testing in later waves, either due to mortality or poor health. Thus, the risk
associated with APOE genotype might be underestimated if those respondents unable to par-
ticipate in later waves were more likely to have at least one ε4 allele than those who did partici-
pate. We were able to perform a simple test of this by replicating the analysis using only the
healthiest and least healthy participants in our sample. We found that our main conclusions
remained the same in these two subsamples. See S1 Appendix for details of this analysis and
further discussion of selection. Third, the relatively low educational attainment of the respon-
dents (about six years on average) raises questions about the generalizability of these findings
to more educated populations, including more recent cohorts of older Taiwanese. Fourth, our
measure of global cognition, although composed of items used in well-validated cognitive
instruments, is not directly comparable to assessments from other studies. Still, we do not feel
that is a major limitation. We intend our results to describe the relationship between APOE
genotype and cognitive function, as measured in one particular way; certainly, other ways of
measuring cognition are valid.
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Finally, several authors argue that the association between APOE genotype and cognitive
decline may be due to confounding from pre-clinical Alzheimer’s disease [11,16,17]. Because
of the nature of our sample creation, it is unlikely that any of our respondents had Alzheimer’s
disease or dementia. However, it is still possible that some were in the early pre-clinical stages
of pathogenic decline; if this were the case, we might have incorrectly classified pathogenic
decline as age-related decline. Similar to other similar studies, we were not able to rule out the
possibility that pre-clinical Alzheimer’s disease was responsible for the association between
APOE and cognitive change. The absence of individuals with Alzheimer’s disease or other
dementias is a further limitation of this study; given the surprising lack of association between
APOE genotype and baseline general cognitive score, it would be interesting to verify whether
APOE genotype predicted Alzheimer’s disease in this sample. If not, it would provide evidence
that genetic risk for cognitive decline—whether neuropathological or age-related—may be
specific to a particular population or ethnicity.
Nevertheless, our study had several important strengths. Consistent, repeated testing
allowed us to compare cognitive trajectories over 11 years in nearly 1400 respondents, and to
examine a detailed assessment of individual cognitive domains on a subsample. Further, we
conducted our study in a nationally representative sample of older Taiwanese adults, a popula-
tion that has been largely neglected in the genetic study of cognition.
This study confirmed the association between APOE genotype and cognitive decline in a
predominantly Han Chinese population of older adults. Additional research is warranted to bet-
ter characterize the genetic determinants of age-related cognitive decline in diverse populations.
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